| INTRODUC TI ON
Rheumatoid arthritis (RA) continues to be a major health burden that affects quality of life and consumes healthcare resources, particularly in low-and middle-income countries such as developing countries in Asia. 1, 2 Better strategic use of agents that delay disease progression, termed disease-modifying anti-rheumatic drugs or DMARDs, has improved outcomes in the past 2 decades. In parallel, development of DMARDs that directly target pro-inflammatory molecules has increased the range of DMARD options available.
DMARDs can be classified into conventional synthetic DMARDs Because new studies had been conducted since the publication of our original document, we searched MEDLINE through PubMed, EMBASE and the Cochrane Library for randomized controlled trials (RCTs), observational studies, and meta-analyses, limited to research in humans, publications in English, from January 2014 to December 2016. The articles were assigned for review to members of the Working Group. To evaluate the evidence from these publications, the group employed the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach to evaluate the evidence from these publications. The GRADE approach is widely seen as the most effective method of linking evidence-quality evaluations to clinical recommendations. 9, 10 Over the next two meetings, the evidence was presented and discussed. According to the GRADE approach, the strength of a recommendation and quality of evidence ("very low", "low", "moderate"
and "high") were assigned grades to yield 1 overall grade (Table 1) . 9, 10 If the Working Group judged that a recommendation lacked sufficiently strong evidence, they agreed to provide their best expert advice but left such recommendations ungraded. The members drafted recommendation statements and refined these as the discussion of evidence proceeded. After the 2nd meeting (3rd overall), the group generated a final set of 16 recommendations for the use of targeted therapy in RA.
A voting group was then convened from APLAR country representatives. Utilizing the modified Delphi technique, the voting group rated their agreement with each recommendation on a 5-point Likert scale (ie, 5, strongly agree; 4, agree; 3, neither agree nor disagree; 2, disagree; 1 strongly disagree); agreement by 75% of total voting members was defined as the threshold for acceptance of a statement. The voting group achieved consensus on all statements in the 1st voting round. 
| RE SULTS
Sixteen recommendations are presented with their level of agreement and overall grade, each followed by a discussion of the past and current evidence that support it (Table 2) . All patients receiving targeted therapy should be closely monitored for therapy-related toxicities Not graded
| Recommendations

10
For RA patients with a history of TB or latent TB (or in whom the risk remains high despite negative screening), targeted therapies other than monoclonal Ab TNFi are preferred
Low
11
In RA patients at increased risk of HBV reactivation, targeted therapies other than RTX are preferred Low
12
Modification of targeted therapy should be performed for failure to achieve remission or low disease activity after 6 mo Not graded
13
In patients with established RA, consideration of tapering or discontinuation of targeted therapy should only be made when the disease is in remission for over 12 can be started as monotherapy or in combination, and that MTX is the preferred csDMARD. The evidence for the efficacy of LEF was presented in three systematic reviews: a Cochrane review showed that LEF was better than placebo with regard to ACR50, HAQ, and radiological progression, and compared with MTX, its use led to similar improvements in ACR50 and reduction of Sharp score progression. 20 The EULAR review and a more recent publication likewise suggested that LEF was as effective as MTX. 17, 21 As early as 1999, LEF was shown to be superior to placebo and as effective as MTX in a RCT in improving RA signs and symptoms, delaying disease progression and improving quality of life. 22 In a subsequent analysis, the safety and efficacy of LEF was sustained over 2 years. 23 After 24 months, LEF was superior to MTX in improving physical function.
SSZ as an alternative to MTX is supported by results from early studies and from recent reviews. A 1998 review showed a statistically significant benefit for SSZ over placebo in improvement of tender and swollen joint scores, and pain. 24 In addition, two RCTs showed no difference in terms of the mean change in DAS and HAQ between MTX and SSZ treatment groups over 1 year. 13, 14 Slowing of radiographic progression was seen in observational studies. 25 More recently, direct comparison of SSZ and MTX in the EULAR review suggested no significant differences in terms of swollen joint count, ACR50, and disability, 17 while the 2002
Cochrane review showed that SSZ had a similar ACR50 response compared with LEF.
20
The csDMARDs cyclosporine, Cochrane review on LEF also showed that the proportion of patients achieving ACR50 was higher in the combination LEF + MTX group compared with MTX alone. The use of targeted therapy has greatly improved RA treatment but has been shown to increase risk of infections, including reactivation of latent viruses. 55, 56 This is relevant particularly in the Asia-Pacific, which has a high prevalence of tuberculosis (TB) and hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections.
59,60
The risk for infections is already higher in individuals with RA.
For example, a cohort study from Taiwan showed an increased risk of HBV infection in those with RA compared with non-RA individuals. 62 The use of targeted agents may raise this risk, as shown by a data review of a TOF development program, in which a high incidence rate of TB in regions endemic for TB was associated with TOF use.
63
Also, studies have suggested a higher risk of cancer in individuals with RA than in the general population. 64, 65 A Swedish cohort study found an increased risk in basal cell carcinoma and squamous cell carcinoma in bDMARD-naive patients with RA compared with the general population. 64 Moreover, results of a meta-analysis of 9 studies showed that patients with RA carry a modest increased risk in overall malignancy, and an increased risk of lymphoma and lung cancer, compared with the general population, although standardized incidence ratio estimates for colorectal and breast cancers showed a decrease in risk. 65 Severe inflammation in immune-mediated diseases is believed to contribute to cellular changes that lead to tumor formation, in which TNF plays a role, 66 but further studies are needed to investigate the underlying mechanisms for the increased or decreased risk of specific cancers observed. 
| TB
The earliest reports of increased TB infection with biological DMARDs for RA, specifically TNFi, were from IFX use. 68, 69 ETN and ANK were also linked to an increased risk of TB. 70, 71 Retrospective studies, including those from Taiwan, Hong Kong, and Korea, showed a higher risk of TB with bDMARDs in patients with RA. 72, 73 Meta-analyses demonstrated an increased risk of TB in patients with RA treated with TNFi. 56, 78 One of these analyses showed that TB incidence rate (IR) was 3.17 times higher in patients with RA than in the general population. Furthermore, TB IR was 17.07 times higher in patients with RA treated with TNFi than the general population. 78 The researchers also evaluated the efficacy of the chemoprophylaxis for latent TB Several international guidelines cite isoniazid (INH) for 6-9 months as standard LTBI treatment for bDMARD candidates.
They also recommend prophylaxis 1-2 months before starting bD-MARD treatment. . 82, 83 Considering that the incidence of HBVr is high among those with chronic HBV infection (HBsAg+) who received bDMARDs, antiviral prophylaxis is thus recommended. 86, 87 HBV serology prior to bD-MARD use, to screen for HBV infection status, is also sensible in our setting. The prophylaxis plan will depend on the individual's status. When indicated, antiviral prophylaxis should be started at least 7 days before initiating immunosuppressive therapy and for at least 6 months (12 months for rituximab) after completion of immunosuppressive treatment. 
| HCV
The risk of reactivation (HCVr) is low in patients with HCV infection.
Studies also suggest that the incidence of HVCr in patients with RA receiving bDMARDs is not as high as HBVr. 94, 95 The suggestion is to determine HCV RNA periodically, but cost is also prohibitive. 
| HIV
There is a lack of data regarding safety of bDMARDs and tsDMARDs 
110
While not all of infections may be vaccine-preventable, it is prudent to plan for protection against those that occur most frequently in patients with RA. The ACR recommends vaccination against the following: Pneumococcus, influenza, HBV, HPV and herpes zoster. ; two of these also studied the influenza vaccine. 111, 116 Patients in the intervention groups were already on TNFi when vaccine was administered. The control groups consisted of patients with RA who had not been on TNFi (or any form of targeted therapy) in the last 6 months and were continued on csDMARDs.
A 2-fold rise in titer defined the vaccine response in all three studies.
Pooled results showed that there was no significant difference in vaccine response between TNFi and control groups. Adverse effects were monitored up to 6 months in 2 of the 3 studies and no significant difference was observed.
Three RCTs studied the effect of non-TNFi (TCZ, TOF, RTX) on immunogenicity of PPSV-23. 112, 114, 115 In the TCZ trial, the intervention group received TCZ + MTX, while the control group received MTX alone. 112 
| Influenza vaccine
Three It is noteworthy that temporary discontinuation of MTX (which is often combined with targeted therapies in RA) 2 weeks before and after influenza vaccination improves the immunogenicity of influenza vaccine. 
| HBV vaccine
A study was presented in the EULAR conference in 2015 on the efficacy of HBV vaccine in patients with RA. 
| HPV and meningococcal vaccine
No RCT on immunogenicity of HPV and meningococcal vaccine in patients with RA taking targeted therapy was found in the literature. In the MTX-naive population, moderate-quality evidence from a Cochrane review confirmed the efficacy of bDMARDs (TNFi ADA, ETN, GOL, and IFX; and non-TNFi ABA, RTX) plus MTX in improving ACR50, HAQ scores, and RA remission rates. However, same-quality evidence showed no difference between TNFi monotherapy (no data for non-TNFi) and MTX. The evidence for slowing of radiographic progression by bDMARD plus MTX was considered as low quality.
122
The efficacy of the JAK inhibitor TOF as monotherapy vs MTX, also in MTX-naive patients, was demonstrated by a double-blind, randomized, placebo-controlled trial. 123 Mean changes in the modified total Sharp score from baseline to month 6 were significantly smaller with TOF than with MTX. Furthermore, the number of patients achieving ACR70 response was significantly greater for the TOF group than the MTX group.
A double-blind, placebo-controlled RCT in early, DMARD-naive RA showed that more patients who started treatment with non-TNFi TCZ with or without MTX were in sustained remission (measured by DAS28) than those who received MTX monotherapy.
124
Cochrane reviews of the use of bDMARDs or TOF for RA in both 127 The investigators compared treatment initiation with TNFi vs combination csDMARDs. For non-responders after 6 months, they prescribed another TNFi in the TNFi-initiation group, and a new TNFi in the csDMARD combination group. HAQ scores favored combination therapy, and there was no difference in disease activity after 6 months or in radiographic damage between groups; they concluded that TNFi were as efficacious as combination csDMARDs in established RA.
A meta-analysis of 8 RCTs (from 10 publications) explored the differences between TNFi combined with a csDMARD and combination csDMARD. Patients included those with early and established RA (5 and 3 studies, respectively). Three studies were conducted in csDMARD-naive patients. Although significant differences were seen between groups in radiographic progression score, ACR50, and ACR70 responses at 6 months favouring TNFi plus csDMARD, these were lost at 24 months.
128
Given the established efficacy of targeted therapy, we recommend their use for controlling disease after failure with csDMARD. 
132
A meta-analysis of long-term extension studies involving patients with chronic, immune-mediated, inflammatory diseases confirmed that TB IR was high with use of TNFi (ETN, IFX, ADA, GOL, and CZP). When analyzed according to disease, the IR in patients with RA with ETN use was lower than with use of TNFi monoclonal antibodies (67.6; 95% CI 12.1-163.9 vs 307.7; 95% CI 184.8-454.9; respectively). High TB IR was also seen with use of non-TNFi TCZ and ABA, but not with RTX, and with the tsDMARD TOF. 133 In phase III and long-term extension studies of TOF for RA, 26 cases of active TB were reported (IRR 0.21; 95% CI 0.14-0.30); 81% of cases occurred in regions with high TB incidence.
63
Another publication looked at TB IR with non-TNFi targeted therapy for rheumatic diseases. The systematic literature review included phase II and III studies, post-marketing surveillance, longterm extension studies, and registry studies on TCZ, RTX, and ABA for RA (ANK was not included), with a population ranging 231-3881 patients across studies, and showed absent or low risk of TB reactivation with use of these agents (IR range of 0-0.38).
134
11. In RA patients at increased risk of HBV reactivation, targeted therapies other than RTX are preferred (95% agreement; grade of evidence low).
Patients with RA with an increased risk of HBV reactivation have the option of using targeted therapies such as TNFi (except RTX) do not appear to be linked with high reactivation rates. We deemed the evidence as low quality due to publication bias.
A meta-analysis of cohort studies showed a relatively low pooled prevalence of HBVr in patients with RA treated with TNFi (3.3%; 95% CI 0.7-7.5), although the authors acknowledged significant heterogeneity among studies. The pooled reactivation rate for patients with chronic overt HBV infection (10.7%) was much higher than those with occult infection (2.6%). For all rheumatic and dermatological conditions treated with TNFi, pooled reactivation rates for ETN and ADA were similar; no cases of reactivation were reported in studies with IFX.
87
HBVr in RA and other chronic inflammatory diseases was primarily reported or evaluated in case reports or small prospective/retrospective studies with use of ETN, IFX, ADA, TCZ, ABA and RTX. 131 A systematic review of such studies using mainly ETN or ADA showed a reactivation rate of 39% among HBsAg+ patients with RA, and 5% in anti-HBc/HBsAg− patients. 135 Other reviews showed an HBVr of 12.3% in HBsAg+ patients and 1.7% in HBsAg-/anti-HBc+ patients with TNFi use for rheumatic diseases. 136, 137 These rates may still be relatively low when considered against the rates with RTX: 27%-80% in HBsAg+ patients and 3%-25% in HBsAg-/anti-HBc+ patients. 138, 139 HBVr has been observed with ABA and TCZ for RA and other chronic inflammatory diseases in case reports and small retrospective studies, but good serological and virological outcomes can be achieved with antiviral prophylaxis.
141
12. Modification of targeted therapy should be performed for failure to achieve remission or low disease activity after 6 months (100% agreement; evidence not graded).
No studies directly addressed the question of the optimal time to switch therapy. At our Working Group meetings, it was agreed that if there is no or inadequate response to targeted therapy, and the treatment causes adverse effects or intolerance, it should be discontinued as soon as possible, and new treatment instituted as soon as it is safe to do so.
First, the question was raised whether targeted therapy was able to induce remission in patients with RA by 6 months. Patients do achieve remission at 6 months, but the proportion is not high: in a Swiss real-world study, at 6 months, about 26% achieved DAS28-defined remission and about 6% achieved remission by Boolean criteria after TNFi treatment.
142
We also searched the literature for the optimal time it takes for bDMARDs to take effect. For IFX 3 mg/kg plus MTX, most of the patients who responded (about 50% of them, by achieving the Paulus 50% index) did so only after 12 weeks. 143 For ADA 40 mg administered every other week, the eventual 15% of patients who would reach ACR70 took 20 weeks. 144 The regimen of ETN + MTX took 20 weeks to optimally reduce the number of tender and swollen joints. 145 GOL required 28 weeks to achieve optimal ACR20 response, but 36 weeks for ACR50 and ACR70 responses. 146 In the BeST study, patients received MTX 25-30 mg/wk with IFX 3 mg/ kg at weeks 0, 2, and 6 and every 8 weeks thereafter, with IFX increased to 6 mg/kg every 8 weeks if the disease was not controlled.
The proportion of patients (about 70%) who achieved ACR20 only reached a plateau after 6 months.
147
A Dutch study of 539 patients assessed the response to TNFi (defined as decrease of DAS28 beyond 1.2) at 3 and 6 months. 148 At 3 months, 44% (233 patients) were considered as responders. Out of the 233, 189 continued receiving the same regimen and at 6 months, 37% of these became responders. The results suggested that lack of response at 3 months did not mean that patients will not respond by 6 months.
Therefore, if treatment with a specific targeted agent was switched to another in 3 months, a proportion of patients who would have responded by 6 months would be deprived of the effect of the drug.
Based on the preceding considerations, we concluded that it is reasonable to switch targeted therapy after a trial of 6 months. For some patients with established RA (usually with long disease duration), achieving personal best disease activities might be considered as an alternative target.
It is also reasonable to optimize the dose of csDMARD if it is used together with a bDMARD when the clinical response is not optimal. In a study of 395 MTX-and bDMARD-naive patients, with the primary endpoint of the proportion of patients achieving DAS28-C-reactive another meta-analysis looking at discontinuation of ETN or ADA showed inferior outcomes compared with continuation, but half of the patients were able to maintain low disease activity for 9-12 months after stopping therapy.
158
Only one trial from the Cochrane review compared disease activity-guided TNFi dose tapering (ADA and ETN) with continuation but reported no statistically significant differences in functional outcomes. 157 Recently, the open-label DRESS RCT showed that disease activity-guided dose reduction (stepwise increase of injection interval every 3 months until disease flare or discontinuation) of ETN or ADA was non-inferior to continuation, based on the proportion of patients with DAS-28 disease flare after 18 months.
159
The best evidence available for the effect of tapering TNFi while continuing MTX during disease remission came from 2 RCTs with patients who had low disease activity (DAS-28 < 3.2) but were not necessarily in remission. Patients achieved stable low disease activity after initial response even with discontinuation of ADA or reduction of ETN dose while continuing MTX, seen after 78 and 88 weeks, respectively. 155, 160 No study addressed the question on the impact of discontinuing non-TNFi or tsDMARD vs continuing these agents, on RA symptoms and adverse events.
The 2016 update of the EULAR recommendations considered the evidence for tapering of bDMARDs in patients with sustained remission to be level IIb strength B. Predictive factors for who will maintain remission after bDMARD withdrawal will require further research. 7 Our recommendation is that tapering or discontinuation of targeted therapy is feasible when disease is in sustained remission. The remission period of >12 months was retained from our 2015 document because the studies cited at present have at least a 12-month duration. Clinicians should be mindful that our statement was based on mainly moderate-quality evidence from very few studies with heterogeneity.
14. For patients with a past history of treated solid cancer, targeted therapies may be used with caution (95% agreement; grade of evidence very low).
Results of studies on risk of malignancy with TNFi have been mixed: some studies have suggested an increased risk of cancer with biologics for RA, whereas others have not, but have shown instead an increase in risk of skin cancer. 66 We considered the 2015 recommendations of the ACR, that is, for untreated and previously treated skin cancers (melanoma and non-melanoma), csDMARDs are recommended over biologics or TNFi. Moreover, the ACR strongly supported RTX over TNFi for previously treated lymphoproliferative disorder, and conditionally recommended combination csDMARDs over ABA, TCZ or TNFi. Individuals with previously treated solid organ malignancy should receive RA therapy as for a patient without a history of solid organ cancer. All evidence for these recommendations were judged as low quality, but RTX over TNFi was strongly favored because of its current role in treatment of lymphoproliferative disorder. The ACR also noted a suggestion of increased risk for lymphoma with TNFi.
6
We looked at evidence from cohort studies, focusing on the analysis of patient registry data for TNFi vs combination csDMARD.
They showed an increased risk of incident malignancies in the presence of previously treated or untreated melanoma skin cancer and non-melanoma skin cancer with TNFi. 161, 162 The risk of incident cancer with previously treated lymphoproliferative disorder was not estimable. 161 Overall, we determined the evidence as very low quality due to imprecision 156, 157 and indirectness.
163
Incident malignancy rates and recurrent malignancy rates did not increase in patients with previously treated solid cancers who received TNFis, when compared with those who received csDMARD for RA, or conventional immunosuppression (non-biologicals) for rheumatic diseases. 161, 164, 165 The evidence for this was very low to low quality.
During the literature search, no studies were retrieved covering nonTNFi biologics. However, a cohort study published recently showed that risk of cancer among patients with RA starting TNFi, TCZ, ABA, or RTX was the same as that of bDMARD-naive, csDMARD-treated patients.
There may be an increased risk for some cancer types (eg, squamous cell carcinoma). 167 In EULAR 2018, a study was presented that examined rates of malignancy (excluding non-melanoma skin cancer) in patients with RA, that found no difference between those newly treated with TCZ compared with those treated with TNFi.
168
Integrating our findings for cancer risk, we generated a recommendation for the use of targeted therapies, "with caution": the apparent low risk of recurrent malignancy is still a signal for potential harm, and not all patients with prior cancer history may be treated safely with targeted therapies. Clinicians should carefully select patients for whom these may be appropriate.
The optimal time to administer targeted therapy after a diagnosis of prior cancer is unknown. In one of the studies, a majority of subjects had a diagnosis of cancer >10 years before receiving TNFi.
161
The approach to the scenario in which a patient is diagnosed with malignancy while on targeted therapy is also undetermined.
15. For patients undergoing major surgery, we recommend temporary discontinuation of targeted therapy and resumption when wound healing is satisfactory (95% agreement; grade of evidence low).
The question of whether targeted therapies increase the risk of postoperative infections in patients with RA was addressed by two systematic reviews, which analyzed studies on use of TNFi. 169 Pregnancy in RA can be complicated by both the disease itself and by the effects of RA medication on the mother, the course of pregnancy, and its outcome. Much of the data on the safe use of targeted therapies during pregnancy and lactation were drawn from observational studies and case reports. The multidisciplinary EULAR task force on antirheumatic drugs during pregnancy and lactation performed a systematic literature review from which they derived clinical points for use during pharmacological management of RA in pregnancy.
172
Among the points to consider regarding targeted therapy use during pregnancy is a recommendation for continued use of TNFi during the 1st trimester. The evidence for this came from cohort studies, case control studies, registry studies, and case reports that showed no increase in rates of miscarriages or congenital malformations vs a control group or background data. ETN and GOL data were from cohort studies or case series with no control group. The EULAR task force stated that ETN and CZP were options to be used throughout pregnancy because they were known to have low placental transfer.
However, the EULAR task force cited insufficient data for nonTNFi bDMARDs RTX, ANK, TCZ, and ABA; their recommendation was that these should be replaced before conception by other medications and should only be considered when all other pregnancycompatible agents fail to control RA disease. TOF had only been studied in one case series, and it should be avoided in pregnancy until further data become available.
Evidence is limited to case reports for use of targeted therapy during lactation, and the EULAR recommendations were based only on expert opinion. TNFi should be continued during lactation; IFX, ADA, ETN, and CZP were mentioned as having low transfer through breast milk. Non-TNFi RTX, ANK, ABA, and TCZ had no data but, in theory, may be considered based on their pharmacological properties when no other agents are available. TOF had no data and should be avoided. 
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